Neumora Therapeutic NMRA 深 沪
已收盘 05-15 16:00:00 美东时间
1.84
-0.130
-6.60%
华盛通- 最 高1.955
- 今 开1.94
- 成交量 82.92万股
- 最 低 1.83
- 昨 收 1.97
- 总市值 3.36亿
- 52周最高 3.65
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 0.6607
- 委 比 79.72%
- 总股本 1.83亿
- 历史最高 21.00
- 量 比 0.55
- 振 幅 6.35%
- 历史最低 0.611
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neumora Therapeutics shares are trading lower. The company reported its Q1 financial results.
Neumora Therapeutics shares are trading lower. The company reported its Q1 fina...
05-07 23:56
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations, shares fall 3.8%. Other stocks also decline.
04-27 20:02
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Neumora Therapeutics Q4 EPS $(0.35) Misses $(0.33) Estimate
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 7.36 percent. This is a 5.41 percent increase over losses of $(0.37) per share
03-30 19:21
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
Neumora FY25 net loss narrows to $237 million; cash drops to $183 million
Neumora FY25 net loss narrows to $237 million; cash drops to $183 million Neumora posted a Q4 net loss of USD 59 million, with loss per share at USD 0.35. Full-year net loss narrowed to USD 237 million, with loss per share improving to USD 1.45. Operating loss widened to USD 241 million as R&D spend
03-30 18:53
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Neumora Therapeutics, Inc. (NASDAQ:NMRA) will release earnings for the fourth q...
03-28 00:26
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Neumora Therapeutics announced it will host a conference call and live webcast on March 30, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available on the Company’s website, www.neumoratx.com, with a replay archived for 30 days. Participants can register here. Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing nov...
03-16 11:00
LB Pharmaceuticals appoints Robert Lenz to board
LB Pharmaceuticals appoints Robert Lenz to board LB Pharmaceuticals appointed Robert Lenz, M.D., Ph.D. to its board of directors. Lenz most recently served as executive vice president and head of R&D at Neumora Therapeutics. Disclaimer: This news brief was created by Public Technologies (PUBT) using
03-09 20:01
